PL2055308T3 - Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki - Google Patents
Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkankiInfo
- Publication number
- PL2055308T3 PL2055308T3 PL07830867T PL07830867T PL2055308T3 PL 2055308 T3 PL2055308 T3 PL 2055308T3 PL 07830867 T PL07830867 T PL 07830867T PL 07830867 T PL07830867 T PL 07830867T PL 2055308 T3 PL2055308 T3 PL 2055308T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical
- damaged tissue
- promoting functional
- functional regeneration
- regeneration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006293582 | 2006-10-30 | ||
EP07830867.3A EP2055308B1 (en) | 2006-10-30 | 2007-10-30 | Pharmaceutical for promoting functional regeneration of damaged tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2055308T3 true PL2055308T3 (pl) | 2017-11-30 |
Family
ID=39344234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07830867T PL2055308T3 (pl) | 2006-10-30 | 2007-10-30 | Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki |
Country Status (13)
Country | Link |
---|---|
US (2) | US20090202500A1 (pl) |
EP (1) | EP2055308B1 (pl) |
JP (2) | JP5308161B2 (pl) |
KR (2) | KR20140115373A (pl) |
CN (1) | CN101374538A (pl) |
AU (1) | AU2007315073A1 (pl) |
CA (1) | CA2636788A1 (pl) |
DK (1) | DK2055308T3 (pl) |
ES (1) | ES2629086T3 (pl) |
HU (1) | HUE035043T2 (pl) |
PL (1) | PL2055308T3 (pl) |
PT (1) | PT2055308T (pl) |
WO (1) | WO2008053892A1 (pl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5814549B2 (ja) * | 2008-04-30 | 2015-11-17 | 株式会社ジェノミックス | 損傷組織の機能的再生促進医薬 |
WO2009133939A1 (ja) * | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
BRPI0911513A2 (pt) | 2008-04-30 | 2016-07-12 | Genomix Co Ltd | métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência |
RU2016135937A (ru) * | 2009-10-28 | 2018-12-11 | Дженомикс Ко., Лтд. | Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь |
JP5706081B2 (ja) * | 2009-10-28 | 2015-04-22 | 株式会社ジェノミックス | 埋め込み式生体内物質採取デバイス |
JP5852773B2 (ja) | 2010-06-01 | 2016-02-03 | ピアス株式会社 | 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用 |
KR102113809B1 (ko) * | 2011-04-26 | 2020-05-21 | 가부시키가이샤 스템림 | 조직 재생을 유도하기 위한 펩티드 및 그의 이용 |
CN102864123B (zh) * | 2011-07-06 | 2015-04-22 | 北京大学第三医院 | 一种外周血间充质干细胞的获得方法及其应用 |
JP6253589B2 (ja) | 2012-10-25 | 2017-12-27 | 株式会社ジェノミックス | Hmgb1断片を利用した新規心筋梗塞の治療法 |
US9688733B2 (en) | 2012-10-25 | 2017-06-27 | Genomix Co., Ltd. | Method for treating spinal cord injury using HMGB1 fragment |
CN103316378B (zh) * | 2013-06-27 | 2014-07-16 | 重庆大学 | 一种hmgb 1修饰的骨组织工程支架材料及其制备方法 |
JP6288672B2 (ja) * | 2014-03-28 | 2018-03-07 | 株式会社巴川製紙所 | 異方性光学フィルム |
JP6452107B2 (ja) * | 2014-09-05 | 2019-01-16 | 国立大学法人 東京大学 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
JP6941417B2 (ja) * | 2016-02-04 | 2021-09-29 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
TWI740964B (zh) * | 2016-06-29 | 2021-10-01 | 南韓商愛茉莉太平洋股份有限公司 | 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法 |
KR102359441B1 (ko) * | 2016-06-29 | 2022-02-09 | (주)아모레퍼시픽 | 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법 |
JP7182162B2 (ja) | 2017-01-27 | 2022-12-02 | 株式会社ステムリム | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 |
AU2018257071B2 (en) * | 2017-04-25 | 2021-11-11 | Shionogi & Co., Ltd. | Peptide for inducing regeneration of tissue, and use thereof |
CN106957821B (zh) * | 2017-04-26 | 2020-04-21 | 南京医科大学第二附属医院 | 一种调控间充质干细胞定向分化的方法 |
JPWO2019017355A1 (ja) * | 2017-07-18 | 2020-05-28 | 株式会社 資生堂 | 間葉系幹細胞誘引剤 |
WO2019107530A1 (ja) | 2017-12-01 | 2019-06-06 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
AU2018376452A1 (en) | 2017-12-01 | 2020-06-25 | Osaka University | Ectodermal mesenchymal stem cells and method for producing same |
CN113194978B (zh) | 2018-10-05 | 2024-03-08 | 斯特姆里姆有限公司 | 具有间充质干细胞的动员活性的肽 |
EP3862018A4 (en) * | 2018-10-05 | 2022-06-29 | Stemrim Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
JP2022506639A (ja) * | 2018-11-04 | 2022-01-17 | フィジーン、エルエルシー | 脳卒中、慢性外傷性脳症、及び外傷性脳損傷を含む脳性低酸素症の治療 |
CN109957015A (zh) * | 2019-04-01 | 2019-07-02 | 中国人民解放军海军军医大学国家肝癌科学中心 | 一种hmgb1封闭性抗体的制备方法及其应用 |
WO2021020509A1 (ja) * | 2019-07-31 | 2021-02-04 | 株式会社ステムリム | 間葉系幹細胞の増殖促進または減少抑制のための組成物 |
EP4058033A1 (en) | 2019-11-12 | 2022-09-21 | Oxford University Innovation Limited | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof |
CN116867909A (zh) * | 2020-12-07 | 2023-10-10 | 社会福祉法人 三星生命公益财团 | 自我维持能力提高的间充质干细胞的筛选方法及由此筛选出的间充质干细胞 |
JP2024515805A (ja) * | 2021-04-27 | 2024-04-10 | アヴィータ・メディカル・インコーポレイテッド | 新たに脱凝集された組織に由来する再生生物活性懸濁液および臨床治療における使用方法 |
AU2022276188A1 (en) | 2021-05-19 | 2023-12-14 | Oxford University Innovation Limited | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
JP3018313B2 (ja) * | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
WO2001008683A1 (en) * | 1999-07-28 | 2001-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Nicotine receptor agonists in stem cell and progenitor cell recruitment |
DE60130435T2 (de) * | 2000-02-24 | 2009-07-23 | Invitrogen Corp., Carlsbad | Gleichzeitige stimulation und konzentration von zellen |
DE10121254A1 (de) * | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind |
US7220723B2 (en) * | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
WO2003043651A1 (en) * | 2001-11-19 | 2003-05-30 | Kyowa Hakko Kogyo Co., Ltd. | Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
MXPA05000302A (es) * | 2002-07-03 | 2005-08-19 | San Raffaele Centro Fond | Uso de hmgb1 en el tratamiento de dano de tejido y/o para promover la reparacion de tejido. |
GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
EP1579221A2 (de) * | 2003-01-03 | 2005-09-28 | Alcedo Biotech GmbH | Verwendungen von hmgb, hmgn, hmga proteinen |
WO2004075855A2 (en) * | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
WO2004084928A1 (en) * | 2003-03-28 | 2004-10-07 | UNIVERSITé LAVAL | S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment |
WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
US20090062187A1 (en) * | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
KR100593397B1 (ko) * | 2004-10-27 | 2006-06-28 | 한국원자력연구소 | 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제 |
WO2007015546A1 (ja) * | 2005-08-04 | 2007-02-08 | Genomix Co., Ltd | 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法 |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
WO2007130725A2 (en) * | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
BRPI0911513A2 (pt) * | 2008-04-30 | 2016-07-12 | Genomix Co Ltd | métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência |
-
2007
- 2007-10-30 JP JP2008542139A patent/JP5308161B2/ja active Active
- 2007-10-30 KR KR1020147023740A patent/KR20140115373A/ko not_active Application Discontinuation
- 2007-10-30 US US12/161,982 patent/US20090202500A1/en not_active Abandoned
- 2007-10-30 AU AU2007315073A patent/AU2007315073A1/en not_active Abandoned
- 2007-10-30 CA CA002636788A patent/CA2636788A1/en not_active Abandoned
- 2007-10-30 DK DK07830867.3T patent/DK2055308T3/en active
- 2007-10-30 WO PCT/JP2007/071133 patent/WO2008053892A1/ja active Application Filing
- 2007-10-30 ES ES07830867.3T patent/ES2629086T3/es active Active
- 2007-10-30 PL PL07830867T patent/PL2055308T3/pl unknown
- 2007-10-30 KR KR1020087018560A patent/KR20090078304A/ko active IP Right Grant
- 2007-10-30 EP EP07830867.3A patent/EP2055308B1/en active Active
- 2007-10-30 PT PT78308673T patent/PT2055308T/pt unknown
- 2007-10-30 HU HUE07830867A patent/HUE035043T2/en unknown
- 2007-10-30 CN CNA2007800038948A patent/CN101374538A/zh active Pending
-
2013
- 2013-06-28 JP JP2013136055A patent/JP2013227330A/ja active Pending
-
2023
- 2023-01-10 US US18/152,249 patent/US20240050460A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2007315073A1 (en) | 2008-05-08 |
WO2008053892A1 (fr) | 2008-05-08 |
ES2629086T3 (es) | 2017-08-07 |
EP2055308A4 (en) | 2010-10-27 |
CA2636788A1 (en) | 2008-05-08 |
JP2013227330A (ja) | 2013-11-07 |
PT2055308T (pt) | 2017-07-05 |
EP2055308B1 (en) | 2017-05-10 |
HUE035043T2 (en) | 2018-05-02 |
JP5308161B2 (ja) | 2013-10-09 |
US20240050460A1 (en) | 2024-02-15 |
KR20140115373A (ko) | 2014-09-30 |
CN101374538A (zh) | 2009-02-25 |
DK2055308T3 (en) | 2017-07-17 |
EP2055308A1 (en) | 2009-05-06 |
KR20090078304A (ko) | 2009-07-17 |
US20090202500A1 (en) | 2009-08-13 |
JPWO2008053892A1 (ja) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2055308T3 (pl) | Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki | |
EP2301560A4 (en) | PHARMACEUTICAL AGENT FOR PROMOTING THE FUNCTIONAL REGENERATION OF DEGRADED TISSUE | |
IL198893A0 (en) | Lipase variants for pharmaceutical use | |
IL287975A (en) | Skin care system | |
IL198663A0 (en) | Tissue treatment methods | |
EP2004809A4 (en) | EX VIVO CREATED TISSUE SYSTEM | |
HK1120234A1 (en) | Medical composition for promotion of skin regeneration | |
EP2077826A4 (en) | METHOD FOR ENHANCING TISSUE REGENERATION | |
EP2087890A4 (en) | PREPARING WITH DELAYED RELEASE FOR TISSUE GENERATION THERAPY | |
GB0725263D0 (en) | Instrument for removing tissue | |
ZA200805761B (en) | Pharmaceutical composition for the treatment of nail disease | |
EP2000169A4 (en) | CATHETER FOR BLOOD EVACUATION | |
EP2098240A4 (en) | MEDIUM TO PROMOTE THE HEALING OF A LIVING BODY | |
EP2210621A4 (en) | COMPOSITION FOR THE TREATMENT OF JOINT DISEASES | |
GB0719248D0 (en) | Compounds and methods for pharmaceutical use | |
GB0816650D0 (en) | Therapeutic bone grwth and regeneration | |
IL197125A0 (en) | Drug combinations for treating airway diseases | |
IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
EP2015741A4 (en) | HISTONE DESACETYLASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATION | |
FI20065514A0 (fi) | Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi | |
IL177114A0 (en) | Disposable swab | |
GB0603773D0 (en) | Surgical electrode | |
EP2070541A4 (en) | MEANS FOR PROMOTING REGENERATION OF HARD FABRIC | |
GB0623740D0 (en) | Treatment of disease | |
IL184236A0 (en) | Glycine reuptake inhibitors for treatment of drug dependence |